secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0000939767-24-000140
Event type: litigation
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis wins patent case against MSN; generic launch blocked until Jan 2030
----------------------------------------------------------------------------

- Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
- Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.
- Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.
- Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/0000939767-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000140/exel-20241015.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer